TASQ binds to a molecule called S100A9 which is expressed in the white blood cells involved in the regulation of immune responses.
As per the terms of the agreement, Ipsen has got exclusive license from Active Biotech to commercialize TASQ worldwide, except for North and South America and Japan, which will be taken care by Active Biotech .
TASQ will be jointly developed by both the parties as a treatment for castrate-resistant prostate cancer, with the possibility to develop TASQ in other cancer indications.
The tie up allows Active Biotech to receive up to EUR200m, which includes EUR25m as an upfront payment and additional payments contingent upon achievement of clinical, regulatory and commercial milestones from Ipsen.
In addition, Ipsen will pay Active Biotech progressive double-digit royalties on its net sales and will conduct and fund a European supportive study in prostate cancer patients out of its R&D budget.
Eventual costs to develop TASQ in future other cancer indications will be shared.
Ipsen chairman and CEO Marc de Garidel said subject to the success of the ongoing phase III clinical trial for the treatment of metastatic castrate-resistant prostate cancer and following market approval, TASQ will perfectly fit in their current portfolio, alongside the sustained-release formulations of Decapeptyl.